AUTHORS
Liangjuan Zhao, Di Fu2, Yaohui Huang Jr3, Ming-Ci Cai4, Yuran Qiu, MD, PhD5, Qing Shi I, Certified Doctor6, Pengpeng Xu, MD7, Li Wang8, Shu Cheng, MD9, Wei Li Zhao III, Certified Doctor10
AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background
Infections frequently complicate peripheral T-cell lymphoma (PTCL), commonly precipitating treatment delays, attenuated does intensity, regimen alterations, and fatal outcomes. However, the temporal evolution of infections throughout PTCL and their relationship with underlying immune vulnerability states remain poorly defined. We delineated infection trajectories from diagnosis through systemic therapy and, in eligible patients, autologous stem cell transplantation (ASCT), profiling clinical and molecular correlates.
Methods
This single-center retrospective study evaluated infectious complications in 152 newly diagnosed patients with PTCL, including nodal T-follicular helper lymphoma (nTFHL; n=116), PTCL-NOS (n=28), and anaplastic large cell lymphoma (ALCL; n=8). Patients received CHOP-based chemotherapy (n=88), epigenetic-containing regimens (n=45), or other frontline regimens (n=14). Analyses were restricted to infections necessitating hospitalization, systemic antimicrobial therapy, or disruption of planned therapy. Infections were defined as microbiologically or clinically documented, and assessed across diagnosis, systemic therapy, and the peri-ASCT period. Whole-genome sequencing (n=152) and transcriptomic profiling (n=138) data from available pretreatment tumor biopsies were integrated with the infection trajectories.
Results
At diagnosis, infections were respiratory-predominant (22/34, 64.7%) and virus-enriched (15/34, 44.1%), with a documented rate of 19.7% (30/152). During systemic therapy, infections shifted to a respiratory-centered mixed phenotype (66/88, 75.0%), comprising viral (33/88; 37.5%), fungal (28/88; 31.8%), and bacterial (20/88; 22.7%) pathogens, affecting 34.7% of patients (51/147). During peri-ASCT, 12 of 27 patients (44.4%) experienced infection, with the spectrum shifting toward a bloodstream/systemic phenotype (8/12, 66.7%), bacterial-dominant (5/12, 41.7%), with all events occurring within day 0–8 after transplant.
Baseline infection tracked with high inflammatory and tumor burden, together with reduced host reserve. Notably, IPI 3–5 was associated with both baseline infection (31.9% vs 11.6%; P=0.007) and susceptibility throughout systemic therapy (HR=3.07; P=0.005). Albumin, as a representative marker of host reserve, remained protective against infection across both CHOP-based (HR=0.37; P=0.019) and epigenetic-containing regimens (HR=0.56; P=0.049). LDH, a surrogate for tumor burden, predicted infection risk under CHOP-based therapy (HR=2.82; P=0.025), whereas inflammatory markers including IL-6 (HR=2.26; P=0.004), soluble IL-2 receptor (HR=2.51; P=0.018), and CRP (HR=1.76; P=0.036) conferred risk in epigenetic-containing regimens.
Genomic profiling uncovered regimen-specific alterations underlying infection susceptibility. On systemic therapy, DNMT3A mutations were associated with risk under CHOP-based regimens (HR=6.04; P=0.044), as were STAT3 mutations (HR=5.09; P=0.004) and NOTCH pathway alterations (HR=2.86; P=0.046) under epigenetic-containing regimens. Transcriptomic profiling identified selective microenvironmental correlates of infection susceptibility. Under epigenetic-containing regimens, resting memory B-cell signatures were associated with reduced infection risk (HR=0.51; P=0.042), whereas immune activation/checkpoint co-expression signatures were associated with increased risk (HR=2.66; P=0.023). No such differences emerged under CHOP-based chemotherapy.
Conclusions
PTCL infection trajectories shift from virus-enriched respiratory infections at diagnosis to mixed opportunistic infections during systemic therapy and bacterial/systemic infections post-ASCT, delineating immune vulnerability states shaped by disease burden, inflammation, treatment context, and molecular features. These findings support phase-specific infection risk stratification, individualized prevention, and adaptation of lymphoma therapy based on infection risk.
DISCLOSURES
Liangjuan Zhao: No relevant conflicts of interest to declare.